Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $29.50.

XNCR has been the subject of several research analyst reports. Wells Fargo & Company dropped their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. William Blair started coverage on Xencor in a research report on Monday, April 21st. They set an “outperform” rating on the stock. Barclays reduced their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, May 8th. Finally, Wedbush restated an “outperform” rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th.

Insider Buying and Selling at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.76% of the company’s stock.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently bought and sold shares of XNCR. Sterling Capital Management LLC boosted its holdings in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Xencor during the 4th quarter worth approximately $34,000. State of Wyoming purchased a new position in shares of Xencor during the 1st quarter worth approximately $34,000. CWM LLC raised its stake in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 2,231 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares during the period.

Xencor Price Performance

XNCR stock opened at $8.06 on Wednesday. The business has a 50 day moving average price of $10.18 and a 200 day moving average price of $17.16. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $573.64 million, a price-to-earnings ratio of -2.52 and a beta of 0.99. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm’s quarterly revenue was up 104.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.11) EPS. Equities research analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.